IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income for the year ended December 31

(in CHF 1 000)

 

 

Notes

 

2020

 

2019

Operating income

 

 

 

 

 

 

Net gains from securities

 

4

 

741 511

 

726 591

Interest income

 

 

 

7

 

41

Dividend income

 

 

 

243

 

1 156

Other income

 

 

 

23

 

378

 

 

 

 

741 784

 

728 166

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

Finance expenses

 

 

 

(883)

 

(1 243)

Foreign exchange losses

 

 

 

(1 857)

 

(1 173)

Administrative expenses

 

8

 

(41 755)

 

(42 375)

Other expenses

 

9

 

(6 040)

 

(5 876)

 

 

 

 

(50 535)

 

(50 667)

Profit/(loss) before tax

 

12

 

691 249

 

677 499

 

 

 

 

 

 

 

Income taxes

 

10

 

(75)

 

(68)

Profit/(loss) for the period

 

 

 

691 174

 

677 431

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

691 174

 

677 431

 

 

 

 

 

 

 

Earnings/(loss) per share in CHF

 

11

 

12.48

 

12.23

Diluted earnings/(loss) per share in CHF

 

11

 

12.48

 

12.23

The notes are an integral part of the consolidated financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer